导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.11% | 2341/4587 |
| 近一周 | -1.23% | 1778/5248 |
| 近一月 | -3.28% | 2249/5205 |
| 近一季 | -8.27% | 3067/5018 |
| 近半年 | -4.86% | 2819/4725 |
| 近一年 | 1.55% | 2357/4241 |
| 近两年 | 51.81% | 1381/2862 |
| 近三年 | 13.00% | 1610/2171 |
| 成立以来 | 8.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.87% 1999/4961 |
15.84% 1623/5312 |
- - |
- - |
| 2025 | 20.44% 2119/4813 |
4.38% 943/3635 |
-1.69% 3249/4076 |
21.69% 1749/4524 |
-3.55% 3293/4813 |
| 2024 | 1.06% 2031/3463 |
-6.12% 2012/2808 |
-5.50% 1733/3014 |
14.90% 1880/3129 |
-0.86% 1533/3463 |
| 2023 | -18.68% 1823/2656 |
4.83% 863/2280 |
-7.09% 1773/2385 |
-10.09% 1950/2515 |
-7.14% 2069/2655 |
| 2022 | -26.12% 1369/2207 |
-18.68% 1376/1919 |
7.84% 424/2016 |
-15.34% 1271/2113 |
-0.48% 1613/2208 |
| 2021 | 6.79% 508/1822 |
-2.44% 643/1255 |
12.81% 308/1330 |
-5.13% 782/1466 |
2.29% 631/1822 |
| 2020 | - - |
- - |
- - |
7.76% 762/1164 |
11.08% 565/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南华中证杭州湾区ETF联接C VS. 长安沪深300非周期A(740101) |